Integrated Diagnostics Appoints Dr. Kenneth C. Fang Chief Medical Officer
26 January 2011
New CMO to lead rapid development and commercialization of blood-based diagnostics for lung cancer and Alzheimer’s disease
SEATTLE — Integrated Diagnostics, an emerging leader in molecular diagnostics founded by Lee Hood, M.D., Ph.D., today announced that Kenneth C. Fang, M.D., has been appointed chief medical officer and vice president of translational research and clinical development. He will lead development of the company’s programs for early detection of complex diseases, including lung cancer and Alzheimer’s disease. Dr. Fang, a distinguished physician-scientist with extensive industry experience in biomarker discovery and molecular diagnostics, was previously senior director for clinical development at XDx and on the faculty at the University of California at San Francisco (UCSF).
“Ken brings an essential – and rare – combination of experience in both molecular diagnostics and therapeutic development as an entrepreneur, a physician, and an academic scientist,” said Albert A. Luderer, Ph.D., CEO of Integrated Diagnostics. “His leadership and broad range of business experience will be integral to Integrated Diagnostics as we continue our swift transition to clinical and commercial development of our blood-based molecular diagnostics. In addition, his academic credentials will be a key asset in our ongoing work with our founding academic partners at The Institute for Systems Biology (ISB) and Caltech – and as we develop new academic partnerships.”
Integrated Diagnostics uses proteomic and genomic techniques to identify and detect organ-specific blood proteins that appear at the earliest stage of disease. This work is based on Dr. Hood’s groundbreaking research in protein blood markers at ISB. By monitoring blood proteins that are only synthesized in the organ of interest, the company’s diagnostics gather systems level knowledge to identify subtle changes that result from disease or treatment.
“Lee Hood and Integrated Diagnostics possess unique technology and a clear vision for bringing the latest advances in molecular diagnostics out of the lab and into the hands of physicians and their patients,” said Dr. Fang. “I am very excited to be working with Lee, Al, and the rest of the team to bring advanced diagnostics to market.”
Prior to joining Integrated Diagnostics, Dr. Fang was a co-founder of Modus BioMedicine, where he led research and development of therapeutics and companion diagnostics to combat rejection of transplanted organs and other immune-mediated diseases. Earlier in his career, for nearly two decades, Dr. Fang was an assistant professor of medicine at UCSF, where he garnered RO1 funding from the National Institutes of Health and was a Cardiovascular Research Institute (CVRI) investigator.
Dr. Fang received his B.A. in biochemistry and his M.D. from the University of Pennsylvania. He completed an internal medicine residency and a fellowship in pulmonary and critical care medicine at UCSF. He later completed postdoctoral research training at CVRI and is board certified in internal medicine, critical care medicine and pulmonology.
About Integrated Diagnostics
Integrated Diagnostics is creating large-scale, blood-based molecular diagnostics that leverage advances in technology to detect disease at its earliest stage. The company, which was founded in October 2009 by genomics and systems biology pioneer Dr. Lee Hood, is developing diagnostic products and measurement technologies that enable physicians and patients to manage complex and important diseases such as cancer, diabetes and Alzheimer’s through blood tests that can monitor tens to hundreds of disease markers simultaneously. The company is conceptually based on a systems view of disease where pathophysiology arises from disease-perturbed networks of proteins, genes and other molecules. Emphasizing sophisticated biomarker selection through informatics, the company is also developing proprietary technology to speed the low-cost, rapid creation of large-scale assays. Investors include InterWest Partners, The Wellcome Trust and BioTechCube Luxembourg. Foundational intellectual property originated from the Institute for Systems Biology and Caltech.